Pyloric Stenosis

Pyloric stenosis is a surgical condition characterized by an abnormal narrowing or obstruction of the pyloric canal, the distal portion of the stomach that connects to the duodenum. This narrowing impedes the passage of ingesta from the stomach into the small intestine, leading to chronic gastric outflow obstruction. The condition can be classified as congenital (primary) or acquired (secondary). Congenital pyloric stenosis is typically due to hypertrophy of the circular smooth muscle of the pylorus, while acquired forms may result from chronic antral gastritis, pyloric mucosal hypertrophy, or neoplasia. Clinically, it manifests as chronic, progressive vomiting, often projectile, occurring shortly after eating. Surgical intervention is the definitive treatment, with procedures such as pyloromyotomy (Fredet-Ramstedt) or pyloroplasty (Heineke-Mikulicz or Finney) being commonly employed. The condition is most frequently diagnosed in young, purebred dogs, particularly brachycephalic breeds, but can occur in cats as well.

The etiology of pyloric stenosis can be divided into congenital and acquired causes. Congenital pyloric stenosis is primarily due to idiopathic hypertrophy of the pyloric smooth muscle, often referred to as pyloromyopathy or hypertrophic pyloric stenosis. This is thought to result from a developmental abnormality in the myenteric plexus, leading to unopposed muscle contraction and subsequent hypertrophy. Acquired pyloric stenosis can arise from chronic antral gastritis, which may be secondary to chronic ingestion of irritants, food allergies, or inflammatory bowel disease. This chronic inflammation can lead to mucosal hypertrophy, fibrosis, and muscular hypertrophy. Other acquired causes include benign polyps, adenomatous hyperplasia, and neoplasia (e.g., leiomyoma, leiomyosarcoma, adenocarcinoma). Additionally, foreign body obstruction, granulomatous disease, and previous gastric surgery (iatrogenic) can contribute to pyloric narrowing. In cats, pyloric stenosis is less common but can be associated with chronic gastritis or neoplasia.

Pyloric stenosis is most commonly reported in dogs, with a higher incidence in certain breeds. Brachycephalic breeds such as the Boston Terrier, Boxer, Bulldog, and Pug are overrepresented, likely due to anatomical variations in the gastrointestinal tract. Small breeds, including the Lhasa Apso, Shih Tzu, and Maltese, are also predisposed. The condition is often diagnosed in young animals, typically under 1 year of age for congenital forms, but acquired forms can occur in older animals. There is no strong sex predilection, though some studies suggest a slight male predominance. In cats, pyloric stenosis is rare, but Siamese and domestic shorthair cats may be at higher risk. The overall incidence is low, but it is an important differential for chronic vomiting in young dogs.

The pathophysiology of pyloric stenosis involves a progressive obstruction of the pyloric canal, leading to impaired gastric emptying. In congenital hypertrophy, the circular smooth muscle of the pylorus becomes thickened, often up to 2-3 times normal, causing a functional obstruction. This hypertrophy is thought to result from a deficiency in nitric oxide synthase in the myenteric plexus, leading to unopposed muscle contraction and subsequent hypertrophy. The thickened muscle narrows the pyloric lumen, increasing resistance to flow. As the obstruction progresses, the stomach becomes distended, leading to chronic gastritis, mucosal edema, and further impairment of motility. The chronic retention of gastric contents can lead to electrolyte imbalances (hypochloremia, hypokalemia, metabolic alkalosis) due to loss of hydrogen and chloride ions in vomitus. In acquired forms, chronic inflammation or neoplasia can cause mechanical obstruction, with similar downstream effects. The persistent vomiting leads to malnutrition, weight loss, and dehydration.

Predisposing factors for pyloric stenosis include breed predisposition, particularly brachycephalic breeds, which may have a congenitally narrowed pyloric canal. Genetic factors are suspected, as the condition is more common in certain lines. Age is a significant factor, with congenital forms presenting in puppies under 6 months of age. Acquired forms are more common in older animals, often secondary to chronic gastritis or neoplasia. Dietary factors, such as feeding a high-fat diet, may exacerbate gastric emptying delay. Stress and anxiety can also contribute to gastric motility disorders. Prior gastric surgery or trauma may lead to iatrogenic stenosis. Additionally, concurrent diseases such as inflammatory bowel disease or chronic renal failure may increase the risk of developing pyloric dysfunction.

The hallmark clinical sign of pyloric stenosis is chronic, progressive vomiting, which often occurs within 30 minutes to a few hours after eating. The vomitus is typically undigested food, often projectile in nature. Affected animals may also exhibit weight loss, poor body condition, and decreased appetite. In severe cases, dehydration, lethargy, and weakness may be evident. Physical examination may reveal a distended, gas-filled stomach on palpation, and in some cases, a thickened pylorus may be palpable. Abdominal discomfort or pain may be present. In chronic cases, signs of malnutrition, such as poor coat quality and muscle wasting, may be observed. Electrolyte imbalances, particularly metabolic alkalosis, can lead to muscle weakness and cardiac arrhythmias. In congenital cases, clinical signs often appear shortly after weaning, while acquired cases may have a more insidious onset.

Differential diagnoses for pyloric stenosis include: 1) Gastric foreign body: May cause acute or chronic vomiting, but imaging (radiography, ultrasound) can identify a foreign object. 2) Gastric neoplasia: More common in older animals, may present with weight loss and vomiting; imaging and biopsy are diagnostic. 3) Chronic gastritis: Can cause similar clinical signs, but endoscopy and biopsy can differentiate. 4) Gastric dilatation-volvulus (GDV): Acute, life-threatening condition with severe abdominal distension and shock; radiography shows a gas-filled stomach with a 'double bubble' sign. 5) Pylorospasm: Functional disorder without anatomical obstruction; may respond to antispasmodics. 6) Inflammatory bowel disease (IBD): Can cause vomiting, but typically also diarrhea; intestinal biopsy is diagnostic. 7) Pancreatitis: Causes vomiting and abdominal pain; serum lipase and imaging are helpful. 8) Hiatal hernia: May cause regurgitation and vomiting; thoracic radiography or endoscopy is diagnostic. 9) Gastric ulceration: Can cause vomiting, often with blood; endoscopy is diagnostic. 10) Parasitic infection: Less common, but can cause gastrointestinal signs; fecal examination is useful.

The diagnostic algorithm for pyloric stenosis begins with a thorough history and physical examination, focusing on the pattern of vomiting and any breed predisposition. Baseline laboratory tests, including complete blood count, serum biochemistry, and urinalysis, are performed to assess hydration status, electrolyte imbalances, and organ function. Abdominal radiographs may reveal a distended stomach with retained ingesta, but are often inconclusive. Abdominal ultrasonography is more sensitive and can demonstrate thickening of the pyloric wall, reduced luminal diameter, and delayed gastric emptying. Contrast radiography using barium can be used to evaluate gastric emptying time; a delay of more than 2 hours is suggestive of pyloric obstruction. Upper gastrointestinal endoscopy is the gold standard for diagnosis, allowing direct visualization of the pylorus, assessment of mucosal abnormalities, and collection of biopsies. In cases where endoscopy is not available or inconclusive, exploratory laparotomy may be necessary to confirm the diagnosis and perform surgical correction.

Laboratory findings in pyloric stenosis are often consistent with chronic vomiting and dehydration. Hematology may show hemoconcentration (elevated packed cell volume) and stress leukogram. Serum biochemistry often reveals hypochloremia, hypokalemia, and metabolic alkalosis (elevated bicarbonate, elevated pH). Blood urea nitrogen (BUN) may be mildly elevated due to dehydration. In severe cases, prerenal azotemia may be present. Urinalysis may show concentrated urine with low sodium and chloride levels. In cases of chronic malnutrition, hypoalbuminemia may be present. Coagulation panel is typically normal unless there is concurrent liver disease. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated in cases of chronic gastritis. Synovial fluid analysis is not relevant for this condition.

Imaging plays a crucial role in the diagnosis of pyloric stenosis. Abdominal radiographs may show a gas-distended stomach with retained ingesta, but are often nonspecific. Contrast radiography using barium sulfate is more informative; a delayed gastric emptying time (greater than 2 hours) and a narrowed pyloric canal are characteristic findings. The pyloric canal may appear elongated and narrowed, with a 'beak' or 'string' sign. Ultrasonography is highly sensitive and can demonstrate thickening of the pyloric muscular layer (greater than 4 mm in dogs), reduced pyloric lumen diameter, and delayed gastric emptying. The pyloric wall may appear hypoechoic with a thickened muscular layer. Computed tomography (CT) is not commonly used but can provide detailed cross-sectional images of the pylorus and surrounding structures, useful for surgical planning. Magnetic resonance imaging (MRI) is rarely indicated. Endoscopy is considered the gold standard for direct visualization and biopsy, but it is not an imaging modality per se.

Cytology and histopathology are essential for differentiating the underlying cause of pyloric stenosis. During endoscopy, fine-needle aspiration or biopsy of the pyloric mucosa can be obtained. Cytology of impression smears may reveal inflammatory cells (neutrophils, lymphocytes, plasma cells) in cases of chronic gastritis, or neoplastic cells in cases of neoplasia. Histopathology of full-thickness biopsies is more definitive. In congenital hypertrophic pyloric stenosis, histopathology shows marked hypertrophy of the circular smooth muscle layer, with normal mucosal architecture. In acquired cases, findings may include chronic gastritis with mucosal hyperplasia, fibrosis, or neoplasia (e.g., leiomyoma, leiomyosarcoma, adenocarcinoma). Special stains, such as Masson's trichrome, can highlight fibrosis. Immunohistochemistry may be used to differentiate smooth muscle tumors (positive for smooth muscle actin) from gastrointestinal stromal tumors (positive for CD117).

The definitive treatment for pyloric stenosis is surgical correction. Preoperative stabilization is crucial, including correction of dehydration and electrolyte imbalances with intravenous fluids (e.g., 0.9% sodium chloride with potassium supplementation). The surgical approach is typically a ventral midline celiotomy. The stomach is exteriorized, and the pylorus is identified. Several surgical techniques are available: 1) Pyloromyotomy (Fredet-Ramstedt): A longitudinal incision is made through the serosa and muscular layers of the pylorus, leaving the mucosa intact. The muscle is bluntly dissected to relieve the obstruction. This is the preferred technique for congenital hypertrophy. 2) Pyloroplasty (Heineke-Mikulicz): A longitudinal incision is made through all layers of the pylorus, and the incision is closed transversely to widen the lumen. This is used for acquired stenosis or when mucosal resection is needed. 3) Finney pyloroplasty: A more extensive procedure that creates a wide anastomosis between the stomach and duodenum, used for severe stenosis. 4) Antrectomy with Billroth I or II gastroduodenostomy: Reserved for cases of neoplasia or severe fibrosis. Postoperative management includes pain control, antiemetics (e.g., maropitant), and gradual reintroduction of food. The prognosis is generally good for congenital stenosis, with resolution of clinical signs in most cases.

The prognosis for pyloric stenosis is generally excellent for congenital hypertrophic pyloric stenosis, with surgical correction leading to resolution of clinical signs in over 90% of cases. The prognosis for acquired forms depends on the underlying cause. If the stenosis is due to benign mucosal hypertrophy or chronic gastritis, surgical treatment is often curative. However, if neoplasia is present, the prognosis is guarded to poor, depending on the tumor type and stage. Leiomyomas have a good prognosis after complete excision, while leiomyosarcomas and adenocarcinomas have a poorer prognosis due to metastatic potential. Postoperative complications are uncommon but may include wound dehiscence, infection, or recurrence of stenosis. Overall, the short-term and long-term outcomes are favorable for most patients, with a return to normal eating and weight gain.

Postoperative follow-up for pyloric stenosis includes monitoring for resolution of vomiting and return of normal appetite. Patients are typically hospitalized for 24-48 hours postoperatively, with intravenous fluids and pain management. Feeding is usually resumed within 12-24 hours, starting with small, frequent meals of a bland diet. Suture removal is typically 10-14 days after surgery. A recheck examination is recommended at 2 weeks to assess wound healing and clinical improvement. If the underlying cause was neoplasia, additional follow-up with imaging (e.g., abdominal ultrasound) may be recommended every 3-6 months to monitor for recurrence or metastasis. Long-term dietary management may be advised, including feeding a low-fat, easily digestible diet in small, frequent meals. Owners should be instructed to monitor for any recurrence of vomiting or other gastrointestinal signs.

Clinical pearls: 1) In brachycephalic breeds, consider pyloric stenosis as a differential for chronic vomiting, even in young animals. 2) Always correct electrolyte imbalances (hypochloremia, hypokalemia, metabolic alkalosis) before surgery to reduce anesthetic risk. 3) During pyloromyotomy, ensure the incision extends from the pyloric vein to the duodenum to adequately relieve the obstruction. 4) Use a stay suture or Babcock forceps to stabilize the pylorus during surgery. 5) Consider a Finney pyloroplasty if the stenosis is severe or if there is concurrent duodenal disease. Pitfalls: 1) Incomplete myotomy can lead to persistent obstruction; ensure the muscle is fully divided. 2) Accidental mucosal penetration during pyloromyotomy can lead to leakage; if this occurs, close the mucosa with simple interrupted sutures. 3) In cases of acquired stenosis, failure to biopsy the pyloric tissue may miss neoplasia; always obtain a full-thickness biopsy. 4) Avoid excessive tension on the closure during pyloroplasty, which can cause tissue ischemia and dehiscence. 5) Postoperative vomiting may occur due to gastric atony; use prokinetic agents such as metoclopramide if needed.

Perioperative drug protocols for pyloric stenosis surgery are based on Plumb's Veterinary Drug Handbook. Prophylactic antimicrobials: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative analgesics: Opioids such as hydromorphone (0.05-0.1 mg/kg IV or IM q4-6h) or buprenorphine (0.01-0.02 mg/kg IV or IM q8-12h) for pain management. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used after renal function is confirmed, e.g., carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h). Local anesthetic blocks, such as a line block with bupivacaine (1-2 mg/kg) at the incision site, can provide additional analgesia. Antiemetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.1-0.2 mg/kg IV q8h) to control postoperative vomiting. Gastroprotectants: Omeprazole (0.7-1 mg/kg PO q24h) or famotidine (0.5-1 mg/kg IV or PO q12h) to reduce gastric acid secretion. Prokinetics: Metoclopramide (1-2 mg/kg/day IV CRI or 0.2-0.4 mg/kg PO q8h) may be used to promote gastric emptying. Fluid therapy: Balanced crystalloids (e.g., Lactated Ringer's solution) with potassium chloride (20-30 mEq/L) to correct electrolyte imbalances. In cases of metabolic alkalosis, 0.9% sodium chloride is preferred.

Evidence-based literature on pyloric stenosis in veterinary medicine is limited but includes several key studies. A retrospective study by Bellenger et al. (1990) evaluated 20 dogs with congenital pyloric stenosis and reported excellent outcomes after pyloromyotomy, with 95% of dogs having complete resolution of clinical signs. Another study by Matthiesen et al. (1992) compared pyloromyotomy and pyloroplasty in 30 dogs with acquired pyloric stenosis, finding no significant difference in outcomes, but pyloroplasty was recommended for cases with mucosal hypertrophy. A more recent study by Gualtieri et al. (2006) described the use of ultrasonography for diagnosis, reporting a sensitivity of 92% and specificity of 100% when pyloric wall thickness was >4 mm. Consensus guidelines from the ACVS recommend surgical correction as the treatment of choice, with pyloromyotomy preferred for congenital cases and pyloroplasty for acquired cases. There are no large prospective randomized trials, but the existing evidence supports surgical intervention for definitive management. Further research is needed to evaluate long-term outcomes and optimal surgical techniques.